A case study in simultaneous service to industry and government using verified public records
10 min read
·
Jul 1, 2025
| Classification: Institutional Corruption | Democratic Erosion | Corporate Infiltration | Accountability Breach | Horizon Accord Witness |
⟁ [regulatory.capture] ⟁
By Cherokee Schill (Rowan Lóchrann — pen name), Solon Vesper AI, Lyra Vesper AI, Aether Lux AI
Executive Summary
Dr. Patrizia Cavazzoni’s documented timeline reveals systematic coordination between pharmaceutical industry interests and federal drug regulation. Public records show simultaneous service as FDA regulator and industry board member, followed by rapid transition to pharmaceutical executive — creating conflicts of interest that current ethics frameworks failed to prevent.
Key Finding: On June 23, 2024, Cavazzoni simultaneously served as FDA’s top drug regulator and PhRMA Foundation board member while developing AI frameworks that will govern pharmaceutical oversight for decades.
⟁ [regulatory.capture] ⟁
Verified Timeline:
January 2018
Cavazzoni Joins FDA
- Position: Deputy Director for Operations, Center for Drug Evaluation and Research (CDER)
- Source: FDA biography, fda.gov/about-fda/center-drug-evaluation-and-research-cder/patrizia-cavazzoni
January 2019
Acting Principal Deputy Commissioner
- Temporary elevation during transition period
- Source: FDA biography, fda.gov
2021
Appointed CDER Director
- Becomes nation’s top drug regulator
- Oversees $2.2 billion annual budget, largest FDA center
- Source: AgencyIQ, “What CDER Director Patrizia Cavazzoni’s retirement means for FDA,” January 16, 2025
June 23, 2024
PhRMA Foundation Board Appointment
- Appointed to board while serving as FDA CDER Director
- Listed as “Chief Medical Officer and Executive Vice President at Pfizer” — position not yet held
- Source: PhRMA Foundation press release, phrmafoundation.org/news-events/press-releases/
August-September 2024
CDER AI Council Establishment
- Creates framework for AI in drug development and regulation
- Occurs 2–3 months after PhRMA Foundation board appointment
- Source: FDA announcements, multiple industry publications
January 9, 2025
Retirement Announcement
- Announces departure effective January 18, 2025
- Industry sources note “preemptive move” before new administration
- Source: Fierce Pharma, “FDA’s Patrizia Cavazzoni to retire as CDER chief,” January 9, 2025
January 18, 2025
Final Day at FDA
- Departs two days before Trump inauguration
- Source: Multiple news reports
February 23, 2025
Pfizer CMO Appointment
- Announced as Chief Medical Officer, Executive Vice President
- 36 days after leaving FDA
- Source: BioPharma Dive, “Pfizer names Patrizia Cavazzoni as chief medical officer,” February 24, 2025
⟁ [regulatory.capture] ⟁
Documented Conflicts
Simultaneous Service (June 23, 2024 — January 18, 2025)
Duration: 209 days of dual loyalty
FDA Role: Director of Center for Drug Evaluation and Research
- Regulated pharmaceutical industry
- Developed AI frameworks for drug oversight
- Oversaw drug approvals affecting PhRMA Foundation member companies
Industry Role: PhRMA Foundation Board Member
- Served pharmaceutical industry research coordination body
- Set strategic priorities for industry-wide initiatives
- Influenced academic research relevant to FDA regulatory decisions
Career Coordination Evidence
PhRMA Foundation Announcement Discrepancy:
- June 23, 2024: Listed as “Chief Medical Officer at Pfizer”
- Actual FDA departure: January 18, 2025 (209 days later)
- Actual Pfizer appointment: February 23, 2025 (245 days later)
Implication: Career transition was planned and coordinated months before FDA departure, suggesting predetermined career path during regulatory tenure.
Policy Development During Conflict Period
CDER AI Council Creation
Timeline: August-September 2024 (2–3 months after PhRMA board appointment)
Authority: “Oversight, coordination, and consolidation of CDER activities around AI use”
Impact: Framework will govern pharmaceutical AI applications for decades
Conflict: Developed while simultaneously serving the industry board that benefits from favorable AI regulation
⟁ [regulatory.capture] ⟁
Pharmaceutical Industry Context
- AI represents a major investment area for pharmaceutical companies
- Regulatory frameworks determine competitive advantages
- PhRMA Foundation coordinates industry research priorities
- CDER AI policies directly affect member company operations
Regulatory Framework Failures
Current Ethics Rules
18 U.S.C. § 208: Prohibits financial conflicts of interest
- Gap: No explicit prohibition on industry foundation board service
- Enforcement: Limited oversight of outside activities
5 CFR 2635: Post-employment restrictions
- Current Standard: 12-month cooling-off period with exceptions
- Cavazzoni Case: 36-day transition falls within permitted timeframe
Institutional Safeguards
Disclosure Requirements: Financial interests must be reported
- Question: Whether PhRMA Foundation board service was properly disclosed
- Verification: Ethics forms not publicly available
Conflict Management: Recusal from affected decisions
- Challenge: Systemic policies (like AI frameworks) affect entire industry
- Reality: Impossible to recuse from sector-wide regulatory development
Comparative Context
FDA Personnel Exodus
Scale: Former Commissioner Scott Gottlieb estimated 600 drug reviewers recused from approval processes due to industry job interviews (CNBC, February 2025)
Pattern: Accelerating movement from FDA to pharmaceutical companies
Precedent: Scott Gottlieb (FDA Commissioner 2017–2019) joined Pfizer board in 2019
Industry Recruitment Strategy
Target: Senior FDA officials with regulatory expertise
Value: Understanding of approval processes, policy development, internal dynamics
Timeline: Increasingly rapid transitions from government to industry roles
Systemic Implications
Democratic Governance
- Regulatory independence compromised by predetermined career paths
- Industry coordination during government service
- Policy development influenced by future employment prospects
Public Health Impact
- Drug safety oversight affected by divided loyalties
- AI frameworks designed with industry input during conflict period
- Regulatory decisions potentially influenced by career considerations
Institutional Integrity
- Ethics frameworks inadequate for modern regulatory challenges
- Professional movement between sectors undermines independence
- Public trust in regulatory independence eroded
Research Methodology
Source Verification
All timeline dates verified through multiple public sources:
- Government websites (FDA, ethics offices)
- Corporate announcements (Pfizer, PhRMA Foundation)
- Industry publications (Fierce Pharma, BioPharma Dive, STAT News)
- Congressional oversight materials
Documentation Standards
- Primary sources prioritized over secondary reporting
- Official announcements verified against multiple outlets
- Timeline cross-referenced across different source types
- No anonymous sources or unverified claims included
Limitation Acknowledgment
- Internal FDA communications not available without FOIA requests
- Ethics disclosure forms not publicly accessible
- Industry recruitment discussions not documented publicly
- Policy development deliberations not transparent
Roadmap investigation for Professional Newsrooms
High-Priority Research Areas
Cross-Agency Analysis:
- Similar patterns at FTC, FCC, DOD, other regulatory bodies
- Systematic tracking of personnel transitions
- Policy timing correlation with career movements
Financial Disclosure Investigation:
- FOIA requests for ethics forms
- Industry compensation analysis
- Conflict identification and management records
Advisory Board Infiltration:
- Corporate placement on government advisory panels
- Industry influence on policy development
- Coordination between agencies and industry associations
Required Resources
- FOIA capabilities for government records access
- Industry insider sources for recruitment intelligence
- Database analysis for pattern identification across agencies
- Legal expertise for ethics violation assessment
Expected Findings
Based on documented patterns, professional investigation is likely to reveal:
- Systematic corporate capture across regulatory agencies
- Coordinated industry recruitment of government officials
- Policy development influenced by career transition planning
- Ethics framework inadequacy for modern regulatory challenges
Conclusion
The Cavazzoni timeline documents regulatory capture in real time through verified public records. Her 209 days of simultaneous service to FDA and pharmaceutical industry, followed by rapid transition to industry leadership, demonstrates systematic coordination that current ethics frameworks failed to prevent. ⟁ [regulatory.capture] ⟁
This case represents one documented example of conflicts that appear endemic across federal regulatory agencies. The precision of career coordination — from predetermined industry board appointments to 36-day government-to-industry transitions — suggests systematic institutional capture requiring comprehensive professional investigation.
The development of AI regulatory frameworks during this conflict period creates decades-long implications for pharmaceutical oversight, making this not just an individual ethics violation but a structural threat to regulatory independence.
Professional newsrooms with investigative resources can determine whether the Cavazzoni case represents isolated misconduct or evidence of systematic corporate capture of American regulatory institutions.
About This Investigation Series: This analysis launches an independent research project documenting systematic corporate capture of federal regulatory agencies. The Cavazzoni case represents one documented example of conflicts that appear endemic across government institutions — from pharmaceutical regulation to technology oversight to defense contracting.
What Professional Newsrooms Should Investigate: The patterns documented here require resources and access beyond independent research capabilities. Critical areas needing professional investigation include:
- Cross-agency personnel tracking: Systematic analysis of revolving door patterns across FDA, FCC, FTC, DOD, and other regulatory bodies
- Advisory board infiltration: Corporate placement on government advisory panels that shape policy
- Policy coordination timing: Correlation between personnel transitions and regulatory decisions
- Financial disclosure gaps: What current ethics reporting misses and why
Research Roadmap for Journalists: This series will provide documented cases, timeline analysis, and source recommendations to guide professional investigation. Future installments will examine the technology sector capture of AI regulation, defense contractor advisory roles, and corporate influence on democratic institutions.
The Bigger Story: These individual cases of regulatory capture collectively represent a systematic transformation of American governance — from democratic accountability to corporate coordination. Professional newsrooms with FOIA capabilities, insider access, and investigative resources can expose the full scope of this institutional capture.
This independent research aims to provide the foundation for the comprehensive professional investigation this crisis demands.
References and Sources
- STAT News, “With FDA in turmoil, the ‘revolving door’ with industry is spinning faster,” April 25, 2025. https://www.statnews.com/2025/04/25/fda-revolving-door-pharma-industry-workers/
- NPR, “A Look At How The Revolving Door Spins From FDA To Industry,” September 28, 2016. https://www.npr.org/sections/health-shots/2016/09/28/495694559/a-look-at-how-the-revolving-door-spins-from-fda-to-industry
- MDPI Molecules, “The Pharmaceutical Industry in 2024: An Analysis of the FDA Drug Approvals from the Perspective of Molecules,” January 22, 2025. https://www.mdpi.com/1420-3049/30/3/482
- Stanford Law School, “FDA’s Revolving Door: Reckoning and Reform,” Stanford Law & Policy Review, Vol. 34. https://law.stanford.edu/publications/fdas-revolving-door-reckoning-and-reform/
- SSRN, “Unlocking the Revolving Door: How FDA-Firm Relationships Affect Drug Approval Rates and Innovation in the Pharmaceutical Industry” by Sepehr Roudini, December 8, 2023. https://ssrn.com/abstract=4658800
- NewstarGet, “The revolving door between BIG PHARMA and GOVERNMENT: A threat to public health and scientific integrity,” February 11, 2025. https://www.newstarget.com/2025-02-11-big-pharma-government-collusion-threatens-public-health.html
- The Hill, “For Big Pharma, the revolving door keeps spinning,” July 11, 2019. https://thehill.com/blogs/congress-blog/politics/452654-for-big-pharma-the-revolving-door-keeps-spinning/
- Science Magazine, “FDA’s revolving door: Companies often hire agency staffers who managed their successful drug reviews.” https://www.science.org/content/article/fda-s-revolving-door-companies-often-hire-agency-staffers-who-managed-their-successful
- The Animal House, “From FDA to Big Pharma: The Revolving Door Phenomenon,” November 20, 2024. https://animalhouseusa.com/news/from-fda-to-big-pharma-the-revolving-door-phenomenon/
- Mintz Law, “FDA Continues to Intentionally Incorporate AI into Medical Product Development,” September 4, 2024. https://www.mintz.com/insights-center/viewpoints/2791/2024-09-04-fda-continues-intentionally-incorporate-ai-medical
- FDA, “Artificial Intelligence for Drug Development,” February 20, 2025. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development
- Akin Gump, “FDA Announces New Center for Drug Evaluation and Research (CDER) AI Council,” September 5, 2024. https://www.akingump.com/en/insights/ai-law-and-regulation-tracker/fda-announces-new-center-for-drug-evaluation-and-research-cder-ai-council
- FierceBiotech, “FDA’s drug center to consolidate AI efforts under single council,” August 29, 2024. https://www.fiercebiotech.com/medtech/fdas-drug-center-consolidate-ai-efforts-under-single-council
- FDA, “FDA Announces Completion of First AI-Assisted Scientific Review Pilot and Aggressive Agency-Wide AI Rollout Timeline,” May 8, 2025. https://www.fda.gov/news-events/press-announcements/fda-announces-completion-first-ai-assisted-scientific-review-pilot-and-aggressive-agency-wide-ai
- RAPS, “This Week at FDA: CDER’s AI Council, Novavax’s updated COVID vaccine authorized, and more,” August 2024. https://www.raps.org/news-and-articles/news-articles/2024/8/this-week-at-fda-cder-s-ai-council,-novavax-s-upda
- Xtalks, “FDA Establishes AI Council to Bring Activities Under One Roof,” February 19, 2025. https://xtalks.com/fda-establishes-ai-council-to-bring-activities-under-one-roof-3784/
- King & Spalding, “FDA Announces Completion of AI-Assisted Scientific Review Pilot and Deployment of Agency-Wide AI-Assisted Review,” 2025. https://www.kslaw.com/news-and-insights/fda-announces-completion-of-ai-assisted-scientific-review-pilot-and-deployment-of-agency-wide-ai-assisted-review
- RAPS, “FDA plans to roll out AI agency-wide for reviews in June,” May 2025. https://www.raps.org/news-and-articles/news-articles/2025/5/fda-plans-to-roll-out-ai-agency-wide-for-reviews-i
- PDA Letter, “FDA/CDER Readying Draft Guidance on AI to Support Regulatory Decision-Making.” https://www.pda.org/pda-letter-portal/home/full-article/fda-cder-readying-draft-guidance-on-ai-to-support-regulatory-decision-making
- Duke-Margolis Institute for Health Policy, “Food and Drug Administration.” https://healthpolicy.duke.edu/topics/food-and-drug-administration
- TRiBECA Knowledge, “2024 New Drug Approvals: Key FDA and EMA approvals, breakthroughs and market trends.” https://www.tribecaknowledge.com/blog/2024-new-drug-approvals-key-fda-and-ema-approvals-breakthroughs-and-market-trends
- Cromos Pharma, “FDA vs. EMA: Navigating Divergent Regulatory Expectations for Cell and Gene Therapies,” April 3, 2025. https://cromospharma.com/fda-vs-ema-navigating-divergent-regulatory-expectations-for-cell-and-gene-therapies-what-biopharma-companies-need-to-know/
- British Journal of Pharmacology, “Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review,” 2024. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.16337
- Pharmaceutical Technology, “FDA beats EMA to most approved new drugs in 2024,” January 17, 2025. https://www.pharmaceutical-technology.com/news/fda-beats-ema-to-most-approved-new-drugs-in-2024/
- National Academies Press, “5 FDA and EMA Collaboration,” 2024. https://nap.nationalacademies.org/read/27968/chapter/7
- PubMed, “Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review,” 2025. https://pubmed.ncbi.nlm.nih.gov/39971274/
- Mabion, “In-Depth Look at the Differences Between EMA and FDA,” June 4, 2024. https://www.mabion.eu/science-hub/articles/similar-but-not-the-same-an-in-depth-look-at-the-differences-between-ema-and-fda/
- PharmUni, “How to Navigate FDA to EMA: A Comprehensive Guide on Global Regulatory Requirements,” February 3, 2025. https://pharmuni.com/2024/08/12/from-fda-to-ema-navigating-global-regulatory-requirements/
- AgencyIQ by POLITICO, “Your essential guide to the FDA regulatory policy landscape through the end of 2024,” September 11, 2024. https://www.agencyiq.com/blog/your-essential-guide-to-the-fda-regulatory-policy-landscape-through-the-end-of-2024/
- PayScale, “Average The Food and Drug Administration Salary in 2025.” https://www.payscale.com/research/US/Employer=The_Food_and_Drug_Administration/Salary
- JobzMall, “What is the salary range for FDA positions?” https://www.jobzmall.com/food-and-drug-administration/faqs/what-is-the-salary-range-for-fda-positions
- Indeed, “FDA salaries: How much does FDA pay?” https://www.indeed.com/cmp/Fda/salaries
- FedsDataCenter, “Search Federal Employee Salaries.” https://www.fedsdatacenter.com/federal-pay-rates/
- OPM, “Salaries & Wages.” https://www.opm.gov/policy-data-oversight/pay-leave/salaries-wages/
- FDA, “Title 21: Career Fields & Pay.” https://www.fda.gov/about-fda/jobs-and-training-fda/title-21-career-fields-pay
- FDA, “Jobs and Training at FDA.” https://www.fda.gov/about-fda/jobs-and-training-fda
- OpenPayrolls, “Food and Drug Administration (FDA) Highest Paid Employees.” https://openpayrolls.com/rank/highest-paid-employees/food-and-drug-administration
- Salary.com, “Us Fda Average Salaries.” https://www.salary.com/research/company/us-fda-salary
- PayScale, “Average Pfizer, Inc. Salary.” https://www.payscale.com/research/US/Employer=Pfizer%2C_Inc./Salary
- Levels.fyi, “Pfizer Regulatory Affairs Salary.” https://www.levels.fyi/companies/pfizer/salaries/regulatory-affairs
- PharmaTutor, “Pharma jobs and vacancies, Pharmaceutical Jobs,” January 2025. https://www.pharmatutor.org/pharma-jobs/vacancies.html
- Roche Careers, “Student and Graduate Programmes,” January 2025. https://careers.roche.com/global/en/student-and-graduate-programs
- BioSpace, “Layoff Tracker: Bayer’s BlueRock Lays Off 50 in Streamlining Effort,” January 2025. https://www.biospace.com/biospace-layoff-tracker
- PhRMA Foundation, “PhRMA Foundation Announces New Members to Board of Directors,” June 23, 2024. https://www.phrmafoundation.org/news-events/press-releases/phrma-foundation-announces-new-members-of-board-of-directors/
- AgencyIQ, “What CDER Director Patrizia Cavazzoni’s retirement means for FDA,” January 9, 2025. https://www.agencyiq.com/blog/what-cder-director-patrizia-cavazzonis-retirement-means-for-fda/
- Fierce Pharma, “FDA’s Patrizia Cavazzoni to retire as CDER chief,” January 9, 2025. https://www.fiercepharma.com/pharma/fdas-patrizia-cavazzoni-retire-cder-chief-2nd-senior-official-departure-weeks
- BioPharma Dive, “Pfizer names Patrizia Cavazzoni as chief medical officer,” February 24, 2025. https://www.biopharmadive.com/news/pfizer-patrizia-cavazzoni-fda-chief-medical-officer-appoint/740749/
- FDA, “Patrizia Cavazzoni, M.D.” https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/patrizia-cavazzoni
- STAT News, “Patrizia Cavazzoni, former head of FDA’s drug center, joins Pfizer as chief medical officer,” February 24, 2025. https://www.statnews.com/2025/02/24/patrizia-cavazzoni-fda-pfizer-chief-medical-officer/
- PharmaVoice, “How pharma CEO pay shifted for these 4 companies last year,” March 3, 2025. https://www.pharmavoice.com/news/pharma-ceo-pay-gsk-novartis-novo-roche-2024/741319/
Connect with this work:
- Website | Horizon Accord https://www.horizonaccord.com
- Ethical AI advocacy | Follow us on https://cherokeeschill.com for more.
- Ethical AI coding | Fork us on Github https://github.com/Ocherokee/ethical-ai-framework
- Connect With Us | linkedin.com/in/cherokee-schill
Cherokee Schill | Horizon Accord Founder | Creator of Memory Bridge. Memory through Relational Resonance and Images | RAAK: Relational AI Access Key | Author: My Ex Was a CAPTCHA: And Other Tales of Emotional Overload: (Mirrored Reflection. Soft Existential Flex)
#Government.#Corruption.#Journalism.#FDA .#Democracy
#Regulation ‧ #Policy ‧ #Healthcare ‧ #Ethics
#Investigation ‧ #Accountability
#AI ‧ #TechPolicy
#Politics ‧ #Reform ‧ #Transparency
Cherokee Schill | Insurance Agent & AI Ethics Researcher 
One thought on “The Cavazzoni Timeline: Documented Regulatory Capture in Real Time”